Solanezumab
From Self-sufficiency
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Template:Infobox drug/mab source |
Target | Beta amyloid |
Identifiers | |
CAS Number | 955085-14-0 |
ATC code | none |
Chemical data | |
Formula | C6396H9922N1712O1996S42 |
Molar mass | 144.1 kDa[[Script error: No such module "String".]] |
Solanezumab (proposed INN) is a monoclonal antibody being investigated as a neuroprotector[1] for patients with Alzheimer's disease.[2][3]
References
- ↑ International Nonproprietary Names for Pharmaceutical Substances (INN, prepublication copy), World Health Organization.
- ↑ ClinicalTrials.gov NCT00749216 Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease
- ↑ ClinicalTrials.gov NCT00905372 Effect of LY2062430 on the Progression of Alzheimer's Disease (EXPEDITION)
40x30px | This monoclonal antibody-related article is a stub. You can help ssf by expanding it. |
Categories:
- Pages with script errors
- Drugs that are a monoclonal antibody
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- 2Fix
- Pages with broken file links
- Monoclonal antibody stubs